Health

  • |

    PhRMA’s Seven-Figure 340B Ad Blitz vs. TrumpRx Lobbying Surge

    ByPhil McCracken

    PhRMA isn’t playing coy. Earlier this month, they rolled out a seven-figure ad campaign targeting the 340B drug discount program, branding it as a cozy corner for hospital exploitation. On the surface: a public service announcement in slick-suit attire. Behind the curtain, though, the same outfit was pouring $12.2 million in Q1 2026 into lobbying efforts—ranking as one of the trade group’s heftiest checks ever written in a quarter, according to Bloomberg Law.

    The paradox here would amuse a cat. While television screens flash with moral indignation over discounted meds for clinics serving the underprivileged, PhRMA’s lobbyists are busy weaving legislative webs in Capitol Hill hallways. If talk is cheap, lobbying clearly doesn’t get the same discount—more like champagne on a shoe-string cut price.

    Here’s the kicker: PhRMA isn’t isolated on this spending spree. As reported by the Sacramento Bee, pharmaceutical companies tied to the TrumpRx initiative shelled out over $130 million in 2025, marking a 23% increase in their lobbying efforts. The narrative is clear: while projecting a wholesome PSA vibe against drug discounts, Big Pharma is wrapping Capitol Hill in a cashmere blanket of influence.

    The 340B program, designed to enable hospitals and clinics to provide affordable meds to needy patients, has been a thorn in PhRMA’s side for a while. They argue the rebates are a windfall for hospitals rather than a direct benefit for patients. You could say it’s a bit like suggesting the hospital uses the program’s ‘gains’ to sneak an espresso machine into the break room.

    Then there’s TrumpRx, a program ostensibly crafted to curb soaring drug prices. Its partners’ heightened lobby spend tells a different story: ensuring the policymaking process is as friendly as a longtime poker buddy.

    The juxtaposition is almost laughable: the louder the commercials, the fatter the lobbying invoices. Public outrage serves as the shiny distraction while the private billing department hums its quiet tune, and yet, who’s footing the bill? Not the executive who’s likely enjoying a cafe’s worth of gratis macchiatos—but rather taxpayers, indirectly contributing to this financial ballet.

    Keep your eyes peeled; as these ad campaigns echo on, the Q2 lobbying disclosures are bound to deliver another round of intrigue—and perhaps, a few more giggles from those tracking lobbyist cologne and receipt trails.

    Sources

  • |

    When the Document Coughs: FDA’s Warning Letter to CareFusion 213, LLC

    ByHugh Jass

    In a world where paperwork often sits quietly, the FDA’s recent Warning Letter to CareFusion 213, LLC, dated April 30, 2026, demands attention. Originating from an October 2025 inspection, the letter unearths a tapestry of sterility failures that reads like a slow-burn horror novel with excessive footnotes.

    The story begins with over 2,500 customer complaints since September 2023, a figure that could make any filing cabinet tremble. Complaints about foreign matter, missing components, and compromised seals adorn these pages like neglected museum artifacts.

    The FDA’s document reveals a chilling absence of deep investigation. Root-cause analyses and Corrective and Preventive Action (CAPA) plans seem to be thrown together with the zeal of a half-hearted prom committee, extending a yawning gap where solutions should stand. The agency was less than impressed.

    Contamination, the document suggests, is less a sporadic guest and more a permanent resident at the CareFusion facility, where sterility test failures and unsatisfactory cleaning procedures hum like a somber background tune. These failings, however, are not newcomers—they bear the familiar refrain of similar violations previously noted in 2016 and again in 2023.

    The FDA’s patience has worn as thin as the pages of this saga, pushing for independent assessments and a retrospective review of the quality system. They’re calling for a systemic overhaul, suggesting that bureaucracy’s usual fixes—training slides and new SOPs—won’t cut it this time.

    As a Becton, Dickinson subsidiary operating out of El Paso, Texas, CareFusion 213, LLC now faces the uncomfortable task of breathing life into the dry script of regulatory compliance. Their response, or lack thereof, will likely dictate the next chapter in this unfolding tale.

    While sterility issues may often gather dust, they can roar to life when someone like Hugh Jass picks up the file and shakes it. As the paperwork coughs to life, the silence in its pages speaks volumes. Next, we await with bated breath to see the response—if any—to this regulatory tome.

    Sources

  • Purdue’s Sentencing Delay, and the Small Fight for a Public Courtroom

    ByHarlan Quill

    I have sat through enough public meetings to recognize civic frustration on contact: folding chairs, stale air, and the slow realization that “procedure” can be a polite way to keep people out. Courtrooms have their own soundtrack. The language is tighter, the stakes are higher, and everything is supposedly neutral. Until the public shows up.

    This week, they did. Outside a federal courthouse in Newark, opioid victims and their families made the oldest American argument: show up in person, stand your ground, and insist the people most affected are not an afterthought.

    What happened: a one-week postponement, for a seat in the room

    On Tuesday, U.S. District Judge Madeline Cox Arleo postponed Purdue Pharma’s criminal sentencing by a week after seeing victims of the opioid crisis gathered outside the courthouse. The hearing had been set up as videoconference-only. She moved it so victims could attend in person and be heard in the room.

    When sentencing happens, she is expected to order Purdue to forfeit $225 million to the Justice Department, tied to a long-running federal resolution of Purdue’s opioid conduct and the company’s broader settlement structure.

    If you are looking for a grand moral reversal, keep walking. A one-week delay is not a reckoning. It is not a cure. It is barely a speed bump.

    But it is something the opioid story has too often lacked: an institution briefly acting like it remembers the public is supposed to be in the building.

    The Paine test: does this serve the people, or the paperwork?

    A remote-only sentencing for a company whose product helped ignite a national public health fire is concentrated convenience. It trims away the discomfort of witnesses in the room and turns a public act into a private-feeling transaction.

    Video hearings have a place. They can reduce travel burdens and improve access for some. But a criminal sentencing is not a quarterly earnings call. The public does not watch justice as content. The public witnesses it as a check on power. That check works best when the institution is willing to endure the inconvenience of people.

    The Orwell check: when “resolution” means closure without accountability

    This saga is soaked in euphemism: “settlement,” “restructuring,” “global resolution,” “moving forward.” Those words often arrive right before responsibility gets turned into administrative finality.

    Delaying sentencing to allow in-person victim attendance does not undo the machinery. But it punctures the language. It says, in courthouse English: this is not just professionals closing a file. The public gets a seat, not just a stream.

    The liberty ledger and the tradeoff

    • Who gains? Victims and families seeking the basics promised by the Crime Victims’ Rights Act: to be present, treated with fairness, and reasonably heard at sentencing. DOJ victim notification materials lay out those rights, including limits on excluding victims from public proceedings absent specific findings.
    • Who is protected by distance? A process that runs smoother when grief is pixelated and the public is a background tab.

    The tradeoff is real: remote technology can help with health, logistics, cost, and access. But “remote access” is different from “remote-only” in a case this publicly consequential. If courts want the benefits of technology without forgetting open courts, the boring answer is still the best one: hybrid access, clear instructions, and transparent reasons for any limits.

    Postpone the sentencing so people can be there. Then do the harder thing: make the outcome legible and worthy of a tragedy that has taken so much. If we cannot manage that, what exactly are we sentencing, the company or our expectations?

  • Purdue, the Opioid Court, and the Right to Show Up

    ByHarlan Quill

    I have sat in enough courthouse hallways to recognize the atmosphere: stale coffee, copier toner, old stone, and that quiet moment when people realize the docket is not a metaphor. Courthouses were built for a simple civic purpose: public accountability in a room you can actually enter. Lately, too many of those rooms have been replaced with a link, a waiting room, and a mute button.

    So I noticed a small but meaningful thing out of Newark, New Jersey: a judge remembered that justice is supposed to be done where the public can show up.

    What happened in the Purdue case

    On April 21, 2026, U.S. District Judge Madeline Cox Arleo postponed Purdue Pharma’s criminal sentencing by one week, moving it from a Zoom hearing to an in-person proceeding set for April 28. The reason was plain: people harmed by the opioid crisis, along with members of the public, arrived and wanted to participate in person. The court accommodated that. Good. Basic. Overdue.

    The underlying case is not small. Purdue’s 2020 guilty plea and the planned sentencing are tied to major penalties and the long tail of an epidemic that has killed more than 1 million Americans since 2000, according to Reuters reporting. Reuters also reported that the sentencing is among the final steps before Purdue can complete a bankruptcy settlement intended to deliver about $7.4 billion to those harmed, with the Sackler family contributing at least $6.5 billion. In the criminal case, Reuters reported the hearing would impose a $3.5 billion fine and $2 billion in forfeiture, with the federal government ultimately waiving repayment rights for all but $225 million so Purdue can direct assets to other opioid creditors.

    The Orwell check: when “access” becomes a settings menu

    We live in a golden age of euphemism. “Remote access” can sound modern and inclusive, and sometimes it helps. But run the Orwell check anyway: when a public proceeding becomes a video link, who controls the waiting room, the mute button, the record, and the feel of shared reality? A courtroom, for all its flaws, is a messy analog check on power. It is harder to stage-manage.

    The liberty ledger

    • Who benefits from remote-only? Efficiency, smoother closure, fewer unpredictable moments.
    • Who pays? Victims and the public, losing not just the right to watch but the right to be felt.

    And yes, the DOJ itself describes victims’ rights, including the right to be reasonably heard at sentencing, in its Crime Victims’ Rights Act materials on the Purdue case page. Those rights should not depend on broadband or a frictionless link.

    The tradeoff: speed vs legitimacy

    A system can be fast, or it can be trusted. Sometimes it can be both, but when forced to choose, legitimacy is the whole game. This one-week delay is not a cure. It is a reminder: the harmed are not an inconvenience to be buffered out of the frame.

    Guardrails we still need

    • Presume in-person access for major public-interest criminal proceedings, with remote access as a supplement.
    • If remote components exist, make the rules clear: entry, comment procedures, recording, and discretion to cut access.
    • Treat opioid accountability like an audit: track spending, demand outcomes, and require readable public reporting.

    After all these years of opioid devastation, why did it take people on the sidewalk to remind the system that victims belong inside the courthouse?

  • A Syringe Adapter That Unwinds, and a Safety System That Shrugs

    ByHarlan Quill

    I can picture the room because American medicine repeats it daily: fluorescent calm, a chart that reads like a court docket, and a clinician trying to keep a line steady while the system asks them to multitask with “small” surprises.

    This surprise is mechanical. A syringe rotating adapter that is supposed to stay tightened can unwind during use. It’s not flirting with anyone’s freedom. It’s flirting with the patient’s bloodstream.

    FDA posts nationwide recall of Aligned Medical angio packs

    On April 20, 2026, the FDA published a company announcement from Windstone Medical Packaging (doing business as Aligned Medical Solutions) about a nationwide recall of two angiography convenience kits: AMS6908E and AMS6908F, sold as Aligned Medical Angio Pack.

    • Problem: the syringe rotating adapter can unwind, creating a loose connection or full disconnection between syringes and a manifold.
    • Risks described: biohazard exposure for staff, blood loss and infection risk for patients, and potential air in the line, including a possible air embolism.
    • Timeline in the notice: Aligned initiated the recall on April 2, 2026; the company announcement is dated April 16, 2026.
    • Scope: distributed nationwide; kits manufactured October 18, 2024 through November 13, 2025; distributed October 28, 2024 through November 28, 2025.
    • Reported outcomes: Aligned says no injuries have been reported to it to date; the same FDA-posted announcement also states three instances were reported to Medline of inadvertent air injection into a patient and one instance of biohazard exposure, with no deaths reported.

    One sentence in the FDA posting is worth underlining: the agency says it’s sharing the company’s announcement “as a public service” and does not endorse the company or product. Not a scandal. Just the operating model, printed in plain sight.

    Why this is bigger than one kit

    Angiography is not a casual errand. When a connection can loosen mid-procedure, that’s not an inconvenience. That’s a design and quality problem with consequences that move faster than memos.

    It also lives inside kit-ification: kits can standardize and speed work, but they can also spread a single component failure across many packs, facilities, and procedures.

    Earlier this month, MedTech Dive reported that Medline removed certain Namic angiographic rotating adaptor control syringes from the market after complaints of disconnections, and that the FDA posted a warning letter tied to the issue. Different notice, overlapping failure mode, similar risks, including air embolism.

    The Orwell check

    “Convenience kit.” “Rotating adapter.” “Field corrective action.” Calm words for an event that can introduce air into a patient’s line. Precision matters, but so does honesty: if the language is gentler than the risk, we’re laundering anxiety through vocabulary.

    The liberty ledger, the Paine test, and the tradeoff

    The liberty ledger: hospitals get purchasing efficiency; manufacturers and distributors get scale and predictable logistics; clinicians get speed and standardization in theory. Patients only benefit if quality control is relentless and warnings are fast, loud, and actionable. Without guardrails, the patient becomes the shock absorber for the system’s efficiency.

    The Paine test:</strong does this expand liberty or concentrate power? Here, it concentrates operational power over what information moves fast, what moves slow, and who has to guess in the meantime.

    The tradeoff:</strong we buy streamlined procurement and lean workflows. We pay with complexity hidden inside packaging and a recall ecosystem that can arrive after the fact.

    • Recall communication should behave like an emergency alert in the places that actually use the products, not a webpage you have to remember to check.
    • Traceability should work at the kit level so facilities are not forced to play inventory detective on a bad day.
    • Safety should be treated as public trust, with clearer standards for timeliness when severe risks are on the table.

    My last question is the only one that matters: if a device failure can plausibly put air in a patient’s line, why do we still accept a system where the loudest alarm is often a web posting?

  • When a Health Plan Leaves Medicaid, It Is Not Just a Business Decision. It Is a Civic One.

    ByHarlan Quill

    Health insurance news usually arrives like corporate weather: a “strategic decision,” a “realignment,” everybody pretend it is just numbers. But when you read it the way people live it, it sounds more like a courthouse hallway: paper, old carpet, and that quiet panic of someone clutching forms like a life raft.

    What Baylor Scott & White Health Plan says it is doing

    In plain English: Baylor Scott & White Health Plan says it intends to exit the Texas Medicaid Managed Care Program at the end of August 2026 and discontinue its individual ACA marketplace plans after December 31, 2026, pending regulatory approval.

    • People affected: about 225,000 Texans (about 125,000 Medicaid members and roughly 100,000 individual marketplace enrollees).
    • Jobs affected: the plan says 321 jobs across Texas are being impacted.

    The health system says its hospitals and clinics will still accept patients who have Medicaid and marketplace coverage. That is true and also confusing, because America loves naming two different entities the same thing and then acting shocked when patients cannot decode the org chart at the pharmacy counter.

    The liberty ledger: who loses choice, and who gets to call it “choice”

    This is not a provider slamming the door on Medicaid patients. It is an insurer backing out of two markets, and telling people they will be reassigned, re-shopped, or reprocessed. The business calls it a transition. Patients experience it as a trust fall with a deadline.

    Medicaid members are least able to absorb disruption: chronic conditions, disability, pregnancy, complex pediatric care, mental health needs, unpredictable work hours, transportation headaches. Even when continuity is promised, people still do the unpaid labor: new cards, new portals, new call trees, new denials, new surprises.

    Marketplace enrollees already live with narrow networks and the annual ritual of asking whether they can afford to be a person with a body next year. A plan ending after December 31, 2026 is not “flexibility.” It is moving day.

    The tradeoff, the Orwell check, and the Paine test

    One report cites the plan pointing to the state Medicaid procurement decision and marketplace “complexities.” Tradeoff: administrative order for the state, churn for patients. Orwell check: “complexities” is the soft word that means someone will lose time, money, or access. “Impacting jobs” is antiseptic, too; jobs are lost or changed.

    Paine test: does this expand liberty, or concentrate power? When a plan exits, remaining plans gain share, the state gains reassignment power, and the patient gets a packet explaining how to keep the same doctor if the new plan agrees they are allowed to.

    Guardrails that should be non-negotiable

    If exits like this are approved, regulators and lawmakers should insist on public, enforceable guardrails: continuity of care with teeth for active treatment; timelines designed for patient reality; plain-language disclosure of reassignment rules and options; and clear, readable rules on privacy and data-sharing during transitions. Sunlight beats euphemism, every time.

    If 225,000 people can be told to switch coverage because the paperwork got complicated, what exactly is the plan for protecting patients when the next exit notice arrives?

  • CMS Wants to ‘Kill the Clipboard.’ Fine. Just Don’t Kill Privacy With It.

    ByHarlan Quill

    The committee-room aroma is scorched coffee plus printer toner, which fits, because American health care is still held together by clipboards, fax machines, and a prayer. Every few years, someone arrives with a glossy “modernization” brochure. The brochure is shiny. The guardrails are usually optional.

    What CMS announced (dates and basics)

    CMS is pushing a major bet: the ACCESS Model, a 10-year, voluntary effort meant to expand technology-supported care for people with Medicare, especially for chronic conditions.

    • CMS says more than 150 organizations have been accepted for the launch.
    • CMS has extended the initial application deadline to May 15, 2026.
    • The model is set to start July 5, 2026.

    CMS also notes that being on the accepted list is not automatic participation. Organizations still have to complete requirements and get final CMS approval.

    ACCESS is aimed at conditions including high blood pressure, diabetes, chronic pain, and depression, and CMS highlights that many accepted organizations have not previously served Medicare beneficiaries.

    “Kill the clipboard,” but watch the back door

    Alongside ACCESS, CMS is marketing a broader HealthTech Ecosystem to end the clipboard era, touting shared standards for identity, security, and interoperability. It has also rolled out a Medicare App Library concept and patient-facing apps intended to streamline check-in and data sharing.

    I am not here to defend the fax machine. I would like to see it indicted. But digital convenience is not automatically a civil-liberties win. Sometimes it is just a faster way to do the wrong thing.

    The Paine test and the Orwell check

    The Paine test: does this expand liberty, or concentrate power? If ACCESS works as promised, it could mean more convenient care, more options, and less bureaucratic warfare for Medicare beneficiaries, with clinicians spending less time on forms and more time treating humans.

    But paper is locally annoying. Digital systems scale. They replicate. They get queried. Once health data becomes a high-speed asset, everyone who touches it starts acting like they deserve a slice.

    The Orwell check: “patient-centered” can become a euphemism for “data-centered.” CMS says the ecosystem is about giving patients control. Good. Now define control: a real right to say no without losing access to care, meaningful limits on secondary uses, clear separation from unrelated enforcement or commercial surveillance, and independent auditing that can prove it.

    The tradeoff: speed, without blank-check consent

    CMS points to “strict guardrails,” including data privacy and security standards, outcome reporting, and quality requirements. Good. But guardrails must be legible to the public and enforceable in daylight.

    Use the extra runway before May 15, 2026 and July 5, 2026 for plain-language privacy rules, strong contractual limits on data use, independent security assessments, and public reporting when things go wrong. Congress should ask the boring questions about retention, access logs, secondary uses, enforcement, and remedies. Watchdogs should FOIA the fine print until it is no longer fine.

    We can modernize. We can even kill the clipboard. Just do not replace it with a quiet consent trap and a fast-moving data pipeline.

  • The FDA’s Peptide Pivot: Freedom, Fraud, and the Fine Print

    ByHarlan Quill

    Federal notices are never loud, but they do have a talent for changing the room temperature. One calendar entry, one committee meeting, and suddenly the folding chairs at the town hall start scraping.

    What the FDA scheduled, and why people care

    This week, the Food and Drug Administration set dates for its Pharmacy Compounding Advisory Committee to meet on July 23 and 24, 2026. The question on the table: whether certain peptides should be allowed back into the compounding pipeline.

    These are not FDA-approved drugs. They are widely promoted in the wellness world, living in the gap between “promising” and “proven,” where marketing often outruns evidence.

    The seven peptides under discussion

    According to the FDA’s advisory committee listing, the July meeting will cover seven substances across two days:

    • July 23: BPC-157, KPV, TB-500, MOTs-C
    • July 24: emideltide (also called DSIP), Semax, Epitalon

    The FDA listing also describes the uses it reviewed for each nomination. That is not an endorsement, but it is a procedural signal that the agency is moving from “no” to “let’s debate the terms.”

    Context: compounding, pressure, and a familiar loophole risk

    STAT reports that in 2023 the FDA removed 19 peptides from the list of substances compounding pharmacies could produce, and that this July panel will consider adding back seven of them. AP reports these peptides are popular, unapproved therapies pushed by wellness influencers and some political figures, and that the FDA’s move follows repeated pledges by Health and Human Services Secretary Robert F. Kennedy Jr. to loosen regulations on peptides.

    Compounding can be a lifeline when patients need customized formulations. It can also become a soft underbelly of oversight, where “tailored care” quietly starts functioning like unregulated manufacturing.

    The Orwell check: when “access” means fewer guardrails

    “Access” is a friendly word. In health policy, it can also mean lowering the evidentiary bar and outsourcing the risk to patients while calling it empowerment. AP’s reporting captures the tension: these products are pitched for a wide range of goals online, while safety data and evidence are thin for many uses.

    The tradeoff, the liberty ledger, and the Paine test

    We buy speed when compounding expands. We pay with clarity about safety and effectiveness, and with accountability when something goes wrong. STAT also reports another meeting is expected before the end of February 2027 to consider additional peptides, which suggests this is a direction, not a one-off.

    The liberty question is not “do we ban everything weird.” It is: who gets more freedom, and who absorbs the uncertainty about dosing, purity, contamination risk, and exaggerated claims? Paine’s simpler version: does this expand liberty for ordinary people, or concentrate power among sellers, promoters, and political appointees who can move markets with a wink?

    Guardrails that should be non-negotiable

    If access expands, guardrails should strengthen: rigorous public quality standards, clear disclosure that products are not FDA-approved, enforced adverse-event reporting, and real oversight of clinics marketing biologically active compounds like miracle apps. Otherwise “freedom” becomes a sales pitch with a flag on it, and patients become the test subjects again.

  • Medicare’s ACCESS experiment is a big bet on digital care. The guardrails need to be bigger.

    ByHarlan Quill

    I was in the library this morning, that quiet little republic of paper and rules, when the news arrived like a stapled packet from a committee room at midnight: Medicare is welcoming a small army of tech-enabled care outfits into older Americans’ daily lives. It is modernization with a friendly interface and a long permissions screen.

    I am not allergic to progress. Chronic disease care in the United States still runs on fax machines, hold music, and exhausted patients trying to keep track of which “little white pill” is the other little white pill. If digital support reduces friction, that is not hype. That is dignity.

    What CMS is doing

    CMS says more than 150 organizations have been accepted for the launch of the Medicare ACCESS model, short for Advancing Chronic Care with Effective, Scalable Solutions. The model is voluntary, runs for 10 years, and is scheduled to launch July 5, 2026. CMS extended the initial application deadline to May 15, 2026, and says later applicants may start January 1, 2027.

    The pitch is simple: technology-supported care for chronic conditions that affect more than two-thirds of people with Medicare, including high blood pressure, diabetes, chronic pain, and depression. Coverage also describes monthly payments tied to outcomes, not just activity, meaning Medicare is trying to pay for better health rather than better marketing.

    CMS also notes that most accepted organizations have not previously served Medicare beneficiaries. That can mean competition. It can also mean new cooks entering the kitchen right before dinner.

    The tradeoff: less waiting room, more data exhaust

    Here is the bargain CMS is asking the public to consider: fewer waiting rooms and more support between visits, in exchange for more data exhaust. Wearables, apps, remote monitoring, asynchronous check-ins, AI triage tools, and outcome dashboards generate information with real value. If you doubt that, check the business models of the modern internet.

    So this is not just a money question. It is a “who gets the map of your life” question: your body, routines, moods, habits, and adherence patterns, plus how long that map is kept and who else gets a copy. Medicare is not a lifestyle brand. It is a public trust.

    The liberty ledger and the Orwell check

    On the plus side of the liberty ledger: beneficiaries gain options and access; providers gain tools to keep patients stable between visits; and CMS gains a results-oriented approach that budget analysts tend to treat like a religious experience.

    On the minus side: digital chronic care can become a one-way mirror where the patient is visible and the system is opaque. People may not know which vendor collects what, which subcontractors process it, and what happens if they want to stop but cannot cleanly untangle their data from the machinery.

    Run the Orwell check on the language and it practically purrs: ACCESS, scalable solutions, outcome-aligned payments, patient-centered. Nice words can still conceal power transfers. CMS does include an important reminder that inclusion on the accepted list is not an endorsement and does not guarantee participation. Good. Keep that skepticism in print.

    The Paine test: liberty or concentrated power?

    The Paine test is whether ACCESS expands freedom for beneficiaries or concentrates power in a new stack of contractors, platforms, and gatekeepers. If it makes care easier while keeping patients in charge of their information, it is a liberty win. If it normalizes always-on collection and makes opting out a maze, that is not modernization. It is perimeter fencing around a public benefit.

    CMS says guardrails exist: enrollment and licensure requirements, privacy and security standards, outcome reporting, and quality standards, plus alignment from private payers representing 165 million members across Medicare Advantage, Medicaid, and commercial coverage. Fine. Now make the limits legible, enforced, and measurable, with results ordinary people can understand.

    So here is the question I would put on the front page, not in the footnotes: if Medicare is going to modernize chronic care, what specific privacy and oversight limits would you demand before you click “I agree”?

  • Medicaid as a Monthly Check-In: Work Rules, Late Instructions, Big Consequences

    ByHarlan Quill

    I grew up thinking government paperwork should behave like a library card: a little effort once, then you get access without a hall monitor trailing you between the shelves.

    This new Medicaid work requirement feels like the opposite. Not a card, a monthly check-in. And the most familiar part is the smell of it: policy first, guardrails later, and a lot of people told the hard part is “just administration.”

    What states are waiting for

    Reuters reported on April 13 that states and insurers still lack key details needed to implement a national Medicaid work requirement slated to take effect next year. The report also warns that federal implementation funding may not cover what states will actually need to build.

    CMS told Reuters it is distributing funds and will provide additional guidance through an interim final rule, but detailed answers on exemptions, qualifying volunteer work, and documentation are not expected until June. That is a real problem in systems where definitions are the policy.

    The Orwell check: “community engagement” is still conditional coverage

    When a program is renamed to sound friendlier, I do the Orwell check. CMS has used the phrase “community engagement requirements” and framed the policy as connecting able-bodied adults to work and engagement opportunities, with states required to implement by January 1, 2027.

    Translated: prove you worked, volunteered, or qualify for an exemption, or coverage can be denied or terminated. That is not encouragement. It is conditionality.

    The liberty ledger: who pays, who shrugs

    States inherit a surveillance chore: verification systems, reporting channels, notices, appeals, and the inevitable glitch parade. Officials described technology costs that may exceed federal funding.

    Insurers brace for a messy rollout. Coverage “churn” can be priced and processed. Families do not experience churn as a spreadsheet event.

    Enrollees lose time and privacy. The Commonwealth Fund explains the basic mechanics: people subject to the policy must document 80 hours a month of work or approved activity, with exemptions for groups like pregnant people and people with disabilities, and states must verify compliance at application and at least every six months. The explainer also notes CMS guidance is expected by June 2026.

    KFF’s summary of the 2025 reconciliation law’s Medicaid provisions describes new administrative requirements, including updating contact information using data sources and sharing information for eligibility integrity purposes. More linkages mean more places for error, misuse, or breach.

    Guardrails before the first termination notice

    • Uniform minimum standards for exemptions, verification, and plain-language notices people can actually understand.
    • Hard privacy rules: data minimization, short retention, audit trails, and real penalties for misuse.
    • Public churn and error reporting, state by state, so “implementation challenges” do not become a euphemism for preventable coverage loss.
    • Serious due process: quick, usable appeals, and terminations treated like the deprivation they are.

    If the rulebook is not ready until June, who exactly is supposed to feel secure about January?

End of content

End of content